T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2024-10-02 DOI:10.1007/s00277-024-06026-x

Yuntong Liu, Jingyu Xu, Wenqiang Yan, Yueshen Ma, Lingna Li, Jian Cui, Rui Lv, Chenxing Du, Lugui Qiu, Gang An

{"title":"T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.","authors":"Yuntong Liu, Jingyu Xu, Wenqiang Yan, Yueshen Ma, Lingna Li, Jian Cui, Rui Lv, Chenxing Du, Lugui Qiu, Gang An","doi":"10.1007/s00277-024-06026-x","DOIUrl":null,"url":null,"abstract":"<p><p>We described 790 patients with newly diagnosed multiple myeloma, including 224 (28.4%) standard risk (SR) patients without t(11;14), 99 (12.5%) patients with t(11;14)alone, 58 (7.3%) with t(11;14) + HR, and 409 (51.8%) in the high-risk cytogenetic abnormality (HRCA) group including t(4;14), t(14;16), t(14;20), C1A1 and/or del(17p) but without t(11;14), to evaluate the impact of t(11;14) in NDMM patients on response rate, response kinetics and survival. Our study showed that NDMM patients in the t(11;14)alone group had similar PFS (49.3 vs. 50.7 months; P = 0.392) and OS (112.4 vs. NR months; P = 0.982) as those in the SR group. However, the t(11;14)alone group exhibited a significantly poorer depth of response compared to the SR group, particularly with a lower MRD negativity rate (60.0% vs. 76.0%, P = 0.009). In the t(11;14)alone group, MRD status did not significantly impact PFS or OS, which was in contrast to the other groups. Response kinetics analyses showed that the t(11;14)alone group had a slower response rate than the other subgroups (t(11;14)alone vs. SR vs. HRCA: median time to MRD negativity = 9.19 vs. 4.25 vs. 4.27 months; P < 0.001). Our study showed that t(11;14)alone was characterized by survival comparable to standard risk cytogenetics despite exhibiting the slowest timing of response onset and lowest plateau of remission, which suggested a relatively indolent clinical course.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-024-06026-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We described 790 patients with newly diagnosed multiple myeloma, including 224 (28.4%) standard risk (SR) patients without t(11;14), 99 (12.5%) patients with t(11;14)alone, 58 (7.3%) with t(11;14) + HR, and 409 (51.8%) in the high-risk cytogenetic abnormality (HRCA) group including t(4;14), t(14;16), t(14;20), C1A1 and/or del(17p) but without t(11;14), to evaluate the impact of t(11;14) in NDMM patients on response rate, response kinetics and survival. Our study showed that NDMM patients in the t(11;14)alone group had similar PFS (49.3 vs. 50.7 months; P = 0.392) and OS (112.4 vs. NR months; P = 0.982) as those in the SR group. However, the t(11;14)alone group exhibited a significantly poorer depth of response compared to the SR group, particularly with a lower MRD negativity rate (60.0% vs. 76.0%, P = 0.009). In the t(11;14)alone group, MRD status did not significantly impact PFS or OS, which was in contrast to the other groups. Response kinetics analyses showed that the t(11;14)alone group had a slower response rate than the other subgroups (t(11;14)alone vs. SR vs. HRCA: median time to MRD negativity = 9.19 vs. 4.25 vs. 4.27 months; P < 0.001). Our study showed that t(11;14)alone was characterized by survival comparable to standard risk cytogenetics despite exhibiting the slowest timing of response onset and lowest plateau of remission, which suggested a relatively indolent clinical course.

查看原文本刊更多论文

T(11;14) 多发性骨髓瘤患者：存活率达标，但反应缓慢且不良。

我们描述了790例新诊断的多发性骨髓瘤患者，其中包括224例（28.4%）无t(11;14)的标准风险（SR）患者，99例（12.5%）单独患有t(11;14)的患者，58例（7.3%）患有t(11;14)+HR的患者，以及409例（51.8%）的高危细胞遗传学异常（HRCA）组患者，包括t（4;14）、t（14;16）、t（14;20）、C1A1和/或del（17p）但无t（11;14）的患者，以评估t（11;14）在NDMM患者中对反应率、反应动力学和生存期的影响。我们的研究显示，仅有t(11;14)组的NDMM患者的PFS（49.3个月 vs. 50.7个月；P = 0.392）和OS（112.4个月 vs. NR个月；P = 0.982）与SR组相似。然而，与SR组相比，单纯t(11;14)组的反应深度明显较差，尤其是MRD阴性率较低（60.0% vs. 76.0%，P = 0.009）。在单独t（11;14）组中，MRD状态对PFS或OS没有显著影响，这与其他组形成鲜明对比。反应动力学分析显示，单纯 t(11;14)组的反应率低于其他亚组（单纯 t(11;14)组 vs. SR 组 vs. HRCA 组：中位 MRD 阴性时间 = 9.19 vs. 4.25 vs. 4.27 个月；P = 0.009）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.